TRPC1 and asthma: Knockdown of TRPC1 via siRNA has been found to significantly impair airway remodeling via decreasing bronchial wall thickness, smooth muscle hypertrophy and hyperplasia, decreased extracellular matrix deposition and infiltration of inflammation in mouse models of asthma sensitized with OVA, showing similar treatment effects to those seen with budesonide (Gottlieb et al., 2008; Li et al., 2019).